Skip to main content

Analytical White Papers

Free analytical and research White Papers on the topic of reimbursement, HTA and evidence requirements for medical devices and IVD tests in Europe

Learn more
See details

Reimbursement summary for angioplasty of arteries of lower extremities

This post presents an extract from our reimbursement analysis for angioplasty of arteries lower extremities using plain and drug-coated balloons (DCBs) for peripheral artery disease in England, France and Germany. Plain balloon angioplasty is reimbursement via DRG solely and DCBs are reimbursement via combination of DRG and add-on reimbursement.
See details

Nine innovations awarded SBRI Healthcare competition for child health in England

On March 6, 2024, the Small Business Research Initiative (SBRI) Healthcare, funded by NHS Accelerated Access Collaborative, awarded £885,000 to support the development of nine innovations that improve the health and well-being of children and young people.

‘Competition 23 - Child Health, Phase 1’ was open to single companies and organizations from the private, public, and third sectors, including large corporates, small and medium enterprises, charities, universities, and NHS providers. It focused on the management of long-term conditions in the priority areas of asthma, epilepsy, and diabetes, as well as the prevention in the areas of obesity and oral health.

The awarded projects will run for up to six months to demonstrate whether the innovations are technically feasible. Subject to funding, innovations that can prove their impact and potential will be able to apply for further funding for prototype development and evaluation. 

The nine awarded innovations concerned e-Health, in-vitro diagnostic, pulmonology, and endocrine fields. Some examples of awarded innovations are provided below: 

  • N-Tidal device (TidalSense), a fast-response capnometer that delivers AI-driven insights for a variety of use cases to clinicians at the point of care within minutes;
  • BioEP (Neuronostics) is a tool to help diagnose children with suspected epilepsy by analyzing brain signals (digital biomarker);
  • Exhale-Dx (Applied Nanodetectors) is a point-of-care AI-based diagnostic breath test platform that predicts asthma exacerbations and monitors asthma control;
  • Non-invasive and needle-free continuous glucose monitor, CGM (Transdermal Diagnostics) for children and young people living with diabetes. The ambition is to create a low-cost, non-invasive, calibration-free, wearable technology;
  • A point-of-care test (William Oak Diagnostics) allowing at-home/primary care testing of micronutrient levels for children with obesity.

See the full details here.

This news is just one of about 300 market access news collected by our team in the premium subscription service Market Access Monitor every week from more than 80 organizations. Access our paid service to stay on top of all developments specifically for your products in Europe (reimbursement news) and globally (HTA news). Access is organized as an online Database and email alert formats. Contact us to get a free, three-month, no-obligation trial.